Johnson & Johnson (JNJ)
176.64
+1.92 (1.10%)
NYSE · Last Trade: Aug 17th, 4:09 PM EDT
Detailed Quote
Previous Close | 174.72 |
---|---|
Open | 175.57 |
Bid | 174.02 |
Ask | 178.00 |
Day's Range | 174.96 - 177.27 |
52 Week Range | 140.68 - 177.26 |
Volume | 9,477,604 |
Market Cap | 464.33B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (2.94%) |
1 Month Average Volume | 8,649,122 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
These three dividend stocks offer steady income and a history of delivering through thick and thin.
Via The Motley Fool · August 16, 2025
Washington D.C. – Hopes for an imminent Federal Reserve interest rate cut have significantly dimmed following the release of hotter-than-expected Producer Price Index (PPI) data on August 14, 2025. The July PPI report revealed a surprising surge in wholesale inflation, forcing traders and economists to reconsider the widespread expectation of
Via MarketMinute · August 14, 2025
The financial markets are currently experiencing a significant sector rotation, as investors increasingly shift their capital from growth-oriented technology stocks towards more value-driven cyclical sectors. This strategic reallocation of assets reflects a broader recalibration of market expectations, signaling a potential late-stage economic cycle or an environment characterized by persistent inflation.
Via MarketMinute · August 14, 2025
The financial markets are once again grappling with the persistent specter of inflation, as the latest reports have sent ripples through the bond market and currency exchange rates. Following a series of economic data releases, the yield on the benchmark 10-year Treasury note has seen a notable climb, while the
Via MarketMinute · August 14, 2025
The United States economy presented a complex and somewhat contradictory picture in the second quarter of 2025, demonstrating a robust 3.0% annualized Gross Domestic Product (GDP) growth, a significant rebound from the previous quarter's contraction. This headline figure suggests a resilient economy, defying some predictions of an imminent slowdown.
Via MarketMinute · August 14, 2025
Palantir Technologies is priced for perfection. Unfortunately, no situation on Wall Street is ever perfect.
Via The Motley Fool · August 14, 2025
The financial markets are abuzz with heightened expectations for a Federal Reserve interest rate cut in September, with probabilities soaring to an overwhelming 96%. This dramatic shift in sentiment comes on the heels of recent inflation data, particularly the July Consumer Price Index (CPI) report, which has largely been interpreted
Via MarketMinute · August 13, 2025
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.
Via Benzinga · August 13, 2025
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.
Via The Motley Fool · August 13, 2025
Via The Motley Fool · August 12, 2025
Dip into a beaten-down market sector for deals on some proven winners.
Via The Motley Fool · August 12, 2025
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic growth. At the heart of these concerns are the tariff policies enacted by former President Donald Trump, which many experts fear could simultaneously drive
Via MarketMinute · August 11, 2025
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.
Via Benzinga · August 11, 2025
Three major dividend names—Waste Management, Eversource, and Johnson & Johnson—each gave investors new reasons to keep them in mind thanks to recent earnings.
Via MarketBeat · August 11, 2025
Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.
Via MarketBeat · August 11, 2025
These top dividend stocks should deliver strong total returns over the next half-decade.
Via The Motley Fool · August 9, 2025
These stocks check off all the boxes for investors no longer receiving a paycheck.
Via The Motley Fool · August 9, 2025
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends.
Via The Motley Fool · August 9, 2025
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.
Via Benzinga · August 8, 2025
Recent economic data from the United States has presented a nuanced picture of the nation's labor market, with a slight uptick in unemployment benefit applications alongside a significantly lower-than-expected nonfarm jobs report. While the increase in jobless claims remains within its recent range and is not immediately indicative of a
Via MarketMinute · August 7, 2025
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on global economies. The U.S. presidential election, a quadrennial event of immense significance, consistently introduces periods of heightened uncertainty and volatility, often culminating
Via MarketMinute · August 7, 2025
The United States economy is currently grappling with a complex and often contradictory narrative, marked by recent weak payrolls data, a discernible slowdown in the labor market, and persistent inflationary pressures. This confluence of factors is sending ripples through the stock market, prompting increased volatility and a significant re-evaluation of
Via MarketMinute · August 7, 2025
A troubling confluence of recent economic data points has sent a shiver through financial markets, reigniting fears of "stagflation"—a dreaded economic scenario characterized by stagnant growth, high unemployment, and persistent inflation. The flat reading in the ISM Services index for July, a significantly weaker-than-expected jobs report, and a narrowing
Via MarketMinute · August 6, 2025
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of stagflation. Weaker-than-expected figures from key indicators, including the ISM Services index, the latest jobs report, and the US trade deficit,
Via MarketMinute · August 6, 2025
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.
Via Benzinga · August 6, 2025